Fig. 5.

SARM protein expression is increased in patients that responded to anti-TNF-α therapy

Patients starting anti-TNF-α treatment were monitored at three time points; pretherapy (T1), 24 hours post-therapy (T2) and 3 months post-therapy (T3). (A) At each time point the DAS28 was measured (n = 6). Data is shown as the mean ± SEM. A paired students t test was used to test significance (*P = 0.0125). The level of SARM protein expression was also measured by western blot at these time points in (B) patients that did not respond to the anti-TNF-α therapy (n = 3) and (C) in those that did respond with a reduction in DAS28 score (n = 3). GAPDH was used as a loading control. DAS28: disease activity score in 28 joints; SARM: sterile-α and armadillo motif containing protein.